Author

Sharon Alroy‐Preis

Observed names: Alroy-Preis, Sharon, S Alroy Preis, Sharon Alroy Preis, Sharon Alroy-Preis

Observed institutions: Dartmouth–Hitchcock Medical Center, Tel Aviv University, Technion – Israel Institute of Technology, Hebrew University of Jerusalem, Sheba Medical Center, Israel Ministry of Health, University of Alabama at Birmingham, New Hampshire Department of Health and Human Services, Weizmann Institute of Science

ORCID: 0009-0006-9106-0341

Observed ORCID: 0009-0006-9106-0341

OpenAlex ID: A5055339900

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

2021 · Eric J Haas, Frederick J Angulo, et al. · The Lancet · 1,607

PDF

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

2021 · Yinon M. Bar-On, Yair Goldberg, et al. · New England Journal of Medicine · 1,154

PDF

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2

2022 · Yair Goldberg, Micha Mandel, et al. · New England Journal of Medicine · 473

PDF

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

2021 · Ital Nemet, Limor Kliker, et al. · New England Journal of Medicine · 413

PDF

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

2021 · Yaniv Lustig, Neta Zuckerman, et al. · Eurosurveillance · 145

PDF

Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study

2021 · Eric J Haas, John M McLaughlin, et al. · The Lancet Infectious Diseases · 134

PDF

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study

2023 · Gili Regev-Yochay, Yaniv Lustig, et al. · The Lancet Microbe · 109

PDF

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

2021 · Yaniv Lustig, Ital Nemet, et al. · New England Journal of Medicine · 67

PDF

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents

2022 · Dror Mevorach, Emilia Anis, et al. · New England Journal of Medicine · 62

PDF

Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022

2022 · Neta S Zuckerman, Itay Bar-Or, et al. · Eurosurveillance · 43

PDF

Performance of the OraQuick HCV Rapid Antibody Test for Screening Exposed Patients in a Hepatitis C Outbreak Investigation

2014 · Fengxiang Gao, Elizabeth A. Talbot, et al. · Journal of Clinical Microbiology · 34

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

2022 · Limor Kliker, Neta Zuckerman, et al. · Eurosurveillance · 33

PDF

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

2021 · Shepherd R. Singer, Frederick J. Angulo, et al. · EClinicalMedicine · 31

PDF

Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel

2021 · Shay Reicher, Ronit Ratzon, et al. · European Journal of Epidemiology · 31

PDF

The Israeli Experience with the “Green Pass” Policy Highlights Issues to Be Considered by Policymakers in Other Countries

2021 · Ruth Waitzberg, Noa Triki, et al. · International Journal of Environmental Research and Public Health · 27

PDF

Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort Study

2024 · Gili Joseph, Ili Margalit, et al. · Viruses · 24

PDF

Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study

2022 · Ofra Amir, Yair Goldberg, et al. · The Lancet Infectious Diseases · 19

PDF

BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals

2021 · Orna Mor, Neta S. Zuckerman, et al. · Journal of Clinical Epidemiology · 19

PDF

Early rise of West Nile fever in Israel, June 2024

2024 · Zohar Mor, Husein Omari, et al. · Eurosurveillance · 18

Environmental surveillance detected type 3 vaccine-derived polioviruses in increasing frequency at multiple sites prior to detection of a poliomyelitis case

2023 · Merav Weil, Danit Sofer, et al. · The Science of The Total Environment · 18

Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician

2018 · Sharon Alroy-Preis, Elizabeth R Daly, et al. · Clinical Infectious Diseases · 18

PDF

Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel

2022 · Dror Mevorach, Emilia Anis, et al. · Circulation · 16

PDF

Reporting of Allergic Reactions During Pfizer-BioNTech BNTT162B2 Vaccination in Israel

2022 · Emilia Anis, Sharon Alroy Preis, et al. · The Journal of Allergy and Clinical Immunology In Practice · 15

PDF

Food supplied to Gaza during seven months of the Hamas-Israel war

2025 · Naomi Fliss-Isakov, Dorit Nitzan, et al. · Israel Journal of Health Policy Research · 13

PDF

Environmental surveillance of a circulating vaccine-derived poliovirus type 2 outbreak in Israel between 2022 and 2023: a genomic epidemiology study

2024 · Neta S Zuckerman, Efrat Bucris, et al. · The Lancet Microbe · 13

Works count: 56

Citation count: 4,588

H-index: 18

I10-index: 26